Zhu Chengyao, Feng Bo, Pan Jiayao, Ma Jun, Hu Binbin, Liu Lunfei
Department of Dermatology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
J Dermatolog Treat. 2025 Dec;36(1):2558995. doi: 10.1080/09546634.2025.2558995. Epub 2025 Sep 10.
Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).
This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients.
Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed. Patients were classified as early itch responders (EIR; ≥4-point reduction in Worst Itch Numeric Rating Scale at week 4) or non-early itch responders (non-EIR). Outcomes included the Dermatology Life Quality Index (DLQI) total score, DLQI 0/1 response rate, DLQI work/study item, and the Patient-Oriented Eczema Measure (POEM) sleep item.
Of 225 patients, 90 were EIR and 135 were non-EIR. The EIR group showed significantly greater improvements in DLQI total score, DLQI 0/1 response rate, and work productivity from week 4 through week 52 compared to the non-EIR group. Sleep disturbance due to itch was also significantly improved in the EIR group from week 4 to week 40, though the difference at week 52 was not statistically significant.
Early itch relief with ivarmacitinib showed significant improvements in QoL, sleep, and work productivity in patients with moderate-to-severe AD.
吡弗替尼（SHR0302）是一种选择性 Janus 激酶-1 抑制剂，是治疗中重度特应性皮炎（AD）的新型药物。
本事后分析评估了吡弗替尼早期缓解瘙痒对受累患者生活质量（QoL）、工作效率和睡眠质量的影响。
分析了一项 III 期试验（NCT04875169）中吡弗替尼治疗组的数据。患者被分为早期瘙痒缓解者（EIR；第 4 周时最差瘙痒数字评定量表评分降低≥4 分）或非早期瘙痒缓解者（非 EIR）。结局指标包括皮肤病生活质量指数（DLQI）总分、DLQI 0/1 缓解率、DLQI 工作/学习项目以及患者导向性湿疹量表（POEM）睡眠项目。
225 例患者中，90 例为 EIR，135 例为非 EIR。与非 EIR 组相比，EIR 组从第 4 周直至第 52 周在 DLQI 总分、DLQI 0/1 缓解率和工作效率方面改善更为显著。从第 4 周直至第 40 周，EIR 组因瘙痒导致的睡眠障碍也显著改善，尽管在第 52 周时差异无统计学意义。
吡弗替尼早期缓解瘙痒在中重度 AD 患者的生活质量、睡眠和工作效率方面显示出显著改善。
